Press Release



 Exhibit 10.1 
 Navidea Biopharmaceuticals Enters into Option Agreement 
 to License
Parkinson’s Disease Imaging Agent 
 — Licensing would add second neuro-imaging candidate to growing Navidea
Biopharmaceuticals pipeline — 
 January 25, 2012 - DUBLIN, OH - Navidea Biopharmaceuticals, Inc.
(NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has entered into an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IAFCT Injection, also called Altropane®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease
and movement disorders. 
 “This option agreement has effectively secured the right for Navidea to obtain a license for
[123I]-E-IAFCT within the next six months. Should we
exercise the option, [123I]-E-IAFCT would provide us not
only with another strong Phase 3 diagnostic imaging asset, but also one that has great synergy with our AZD4694 PET imaging agent which we are developing as an aid in the diagnosis of Alzheimer’s disease. Together, we believe these programs
provide us with a robust franchise in precision neuro-imaging diagnostics,” said Dr. Thomas Tulip, EVP and Chief Business Officer of Navidea. 
 The option agreement provides Navidea with exclusive rights for a period of up to six months to perform final due diligence and prepare the documentation necessary to enter into a definitive license
agreement for [123I]-E-IACFT. Under the terms of the
option agreement, Navidea paid Alseres an option fee of $500,000 for the exclusive right to negotiate a definitive license agreement by June 30, 2012. Navidea can extend the option period from June 30, 2012, to July 31, 2012, for an
additional $250,000. The option agreement anticipates that Navidea will issue Alseres 400,000 shares of Navidea common stock upon execution of the definitive license agreement. The option also anticipates that the license agreement will provide for
contingent milestone payments of up to $3.0 million, $2.75 million of which will principally occur at the time of product registration or upon commercial sales, and the issuance of up to an additional 1.05 million shares of Navidea stock,
950,000 shares of which are issuable at the time of product registration or upon commercial sales. In addition, the license terms outlined in the option agreement anticipate royalties on net sales of the approved product which are consistent with
industry-standard terms. 
 [123I]-E-IACFT is a patented, novel, small molecule radiopharmaceutical used with single photon emission computed
tomography (SPECT) imaging to identify the status of specific regions in the brains of patients suspected of having Parkinson’s disease. The agent binds to the dopamine transporter (DAT) on the cell surface of dopaminergic neurons in the
striatum and substantia nigra regions of the brain. Loss of these neurons is a widely recognized hallmark of Parkinson’s disease. 
 [123I]-E-IACFT has
 been administered to over 600 subjects to date. A Phase 3 Special Protocol Assessment (SPA) for [123I]-E-IACFT is already in place with the U.S. Food and Drug Administration (FDA) and over 50 subjects have been enrolled to establish a training data base. Results from clinical trials have demonstrated
that [123I]-E-IACFT has high affinity for DAT and rapid
kinetics which enable the generation of clean images quickly, beginning within about 20 minutes after injection while other agents typically have waiting periods from 4 to 24 hours before imaging can occur. In addition to its potential use as an aid
in the differential diagnosis of Parkinson’s disease and movement disorders, [123I]-E-IACFT may also be useful in the diagnosis of Dementia with Lewy Bodies (DLB), one of the most common forms of dementia after Alzheimer’s disease. 







 “The diagnostic dilemma in movement disorders remains a pressing medical need. It
is difficult for physicians to differentiate Parkinson’s disease from non-degenerative movement disorders, especially during the period soon after onset of symptoms, where diagnostic uncertainty and inaccuracy can be high,” said
Dr. Tulip. “Having worked with this agent previously, I am very familiar with its strong performance characteristics and potential marketplace advantages. We believe that [123I]-E-IACFT has the potential to be a best-in-class imaging agent to improve diagnostic accuracy in this class of
disorders.” 
 “[123I]-E-IACFT is a compelling, Phase 3 diagnostic agent that may be able to help the millions of patients with movement
disorders and their physicians arrive at a more timely and accurate diagnosis,” said Peter G. Savas, CEO of Alseres. “We are pleased to have identified in Navidea a potential partner with the focus, dedication, expertise and resources to
complete the development and commercialization of this promising agent. We look forward to completing the license agreement with Navidea and to Navidea moving forward with development and commercialization of [123I]-E-IACFT.” 

“We are pleased to have found another high-quality, late-stage diagnostic radiopharmaceutical that is well aligned with our
overall growth plans,” said Dr. Mark Pykett, President and CEO of Navidea. “The [123I]-E-IACFT program is consistent with our strategy to build our precision radiopharmaceutical pipeline with later stage, high value diagnostics aimed at important unmet medical needs. We believe this
program represents an excellent strategic fit for us at this time.” 
 About Navidea 

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of
precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the presence and status of undetected disease and enable better diagnostic accuracy, clinical
decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective
acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com. 
 The Private
Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking
statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of
the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the
Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and
distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and
Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements. 

Contact: 
 Navidea
Biopharmaceuticals, Inc. – Brent Larson, Sr. VP & CFO – (614) 822-2330